SG155901A1 - Enzyme inhibitors and uses thereof - Google Patents
Enzyme inhibitors and uses thereofInfo
- Publication number
- SG155901A1 SG155901A1 SG200905965-0A SG2009059650A SG155901A1 SG 155901 A1 SG155901 A1 SG 155901A1 SG 2009059650 A SG2009059650 A SG 2009059650A SG 155901 A1 SG155901 A1 SG 155901A1
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- present
- irap
- enzyme inhibitors
- lactation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004905182A AU2004905182A0 (en) | 2004-09-09 | Enzyme inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG155901A1 true SG155901A1 (en) | 2009-10-29 |
Family
ID=36036029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200905965-0A SG155901A1 (en) | 2004-09-09 | 2005-09-09 | Enzyme inhibitors and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080194636A1 (https=) |
| EP (1) | EP1789079B1 (https=) |
| JP (1) | JP5031567B2 (https=) |
| KR (1) | KR20070100878A (https=) |
| CN (1) | CN101039690A (https=) |
| CA (1) | CA2579768A1 (https=) |
| DK (1) | DK1789079T3 (https=) |
| ES (1) | ES2403340T3 (https=) |
| IL (1) | IL181819A (https=) |
| NZ (1) | NZ553688A (https=) |
| SG (1) | SG155901A1 (https=) |
| WO (1) | WO2006026832A1 (https=) |
| ZA (1) | ZA200702041B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009065169A1 (en) | 2007-11-19 | 2009-05-28 | Howard Florey Institute | Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof |
| CN101284820B (zh) * | 2008-04-25 | 2011-05-04 | 南昌大学 | 一种氨肽酶抑制剂及合成方法 |
| CN103848805A (zh) * | 2012-12-06 | 2014-06-11 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103896900A (zh) * | 2012-12-25 | 2014-07-02 | 韩冰 | 一类具有神经保护作用的化合物及其制备方法和用途 |
| MX373831B (es) | 2014-05-28 | 2020-03-25 | Astellas Pharma Inc | Derivado de piridina. |
| AR102849A1 (es) | 2015-03-09 | 2017-03-29 | Astellas Pharma Inc | Compuesto de piridina bicíclica |
| CA3017028C (en) | 2015-07-30 | 2020-06-16 | Monash University | Fibrotic treatment |
| EP4440570A1 (en) | 2021-12-01 | 2024-10-09 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Irap inhibitors for use in the treatment of inflammatory diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284868A (en) * | 1991-10-09 | 1994-02-08 | Eli Lilly And Company | Pharmaceutical compounds |
| US5281619A (en) | 1992-09-25 | 1994-01-25 | Eli Lilly And Company | Therapy for diabetic complications |
| EP1004584A3 (en) | 1992-11-18 | 2000-07-05 | Eli Lilly And Company Limited | Pyranoquinoline derivatives as inhibitors of cell proliferation |
| US6680332B1 (en) * | 1999-06-04 | 2004-01-20 | Euro-Celtique S.A. | Substituted 5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of AMPA |
| US7053117B2 (en) * | 2001-05-16 | 2006-05-30 | Cytovia, Inc. | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| WO2003011304A1 (en) * | 2001-08-02 | 2003-02-13 | Howard Florey Institute Of Experimental Physiology And Medicine | Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity |
| US20030114418A1 (en) * | 2001-08-14 | 2003-06-19 | Pharmacia Corporation | Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor |
| ES2252656T3 (es) * | 2002-02-13 | 2006-05-16 | F. Hoffmann-La Roche Ag | Nuevos derivados de piridina y quinolina. |
| WO2009065169A1 (en) * | 2007-11-19 | 2009-05-28 | Howard Florey Institute | Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof |
-
2005
- 2005-09-09 NZ NZ553688A patent/NZ553688A/en not_active IP Right Cessation
- 2005-09-09 CN CNA2005800353360A patent/CN101039690A/zh active Pending
- 2005-09-09 DK DK05778990.1T patent/DK1789079T3/da active
- 2005-09-09 EP EP05778990A patent/EP1789079B1/en not_active Expired - Lifetime
- 2005-09-09 CA CA002579768A patent/CA2579768A1/en not_active Abandoned
- 2005-09-09 ZA ZA200702041A patent/ZA200702041B/xx unknown
- 2005-09-09 KR KR1020077008049A patent/KR20070100878A/ko not_active Withdrawn
- 2005-09-09 SG SG200905965-0A patent/SG155901A1/en unknown
- 2005-09-09 ES ES05778990T patent/ES2403340T3/es not_active Expired - Lifetime
- 2005-09-09 JP JP2007530547A patent/JP5031567B2/ja not_active Expired - Fee Related
- 2005-09-09 WO PCT/AU2005/001380 patent/WO2006026832A1/en not_active Ceased
- 2005-09-09 US US11/662,392 patent/US20080194636A1/en not_active Abandoned
-
2007
- 2007-03-08 IL IL181819A patent/IL181819A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL181819A0 (en) | 2007-07-04 |
| EP1789079A4 (en) | 2010-09-01 |
| ZA200702041B (en) | 2008-09-25 |
| EP1789079B1 (en) | 2012-11-07 |
| JP2008512395A (ja) | 2008-04-24 |
| DK1789079T3 (da) | 2013-03-11 |
| US20080194636A1 (en) | 2008-08-14 |
| KR20070100878A (ko) | 2007-10-12 |
| WO2006026832A1 (en) | 2006-03-16 |
| EP1789079A1 (en) | 2007-05-30 |
| ES2403340T3 (es) | 2013-05-17 |
| JP5031567B2 (ja) | 2012-09-19 |
| CA2579768A1 (en) | 2006-03-16 |
| CN101039690A (zh) | 2007-09-19 |
| NZ553688A (en) | 2011-05-27 |
| IL181819A (en) | 2013-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| EA200870446A1 (ru) | Пиридон сульфонамиды и пиридон сульфамиды в качестве ингибиторов мек | |
| EP2493507A4 (en) | AX213 AND AX132 PCSK9 ANTAGONISTS AND VARIANTS THEREOF | |
| EA200800664A1 (ru) | Производные пирролопиримидина в качестве ингибиторов syk | |
| GEP20104974B (en) | Carbonylamino pyrrolopyrazoles, protent kinase inhibitors | |
| WO2008057459A3 (en) | Antagonists of pcsk9 | |
| WO2008057457A3 (en) | Antagonists of pcsk9 | |
| WO2008057458A3 (en) | Antagonists of pcsk9 | |
| WO2008133647A3 (en) | Antagonists of pcsk9 | |
| GEP20115302B (en) | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | |
| GB0402137D0 (en) | Novel compounds | |
| EA200900285A1 (ru) | Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов | |
| GB0402143D0 (en) | Novel compounds | |
| MXPA06011327A (es) | Azaindoles utiles como inhibidores de jak y otras proteinas cinasas. | |
| TW200604168A (en) | Azaindoles useful as inhibitors of rock and other protein kinases | |
| NO20061194L (no) | Mitotiske kinesininbibitorer | |
| ATE396731T1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| SG170828A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
| SE0201980D0 (sv) | Novel compounds | |
| EP2168578A3 (en) | Thiazole based inhibitors of atp-utilizing enyzmes | |
| TW200634012A (en) | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | |
| DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| MX2007004841A (es) | Triazoles utiles como inhibidores de proteinas cinasas. | |
| PH12012502070A1 (en) | Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders | |
| CY1107342T1 (el) | Χρηση παραγωγων νιτριλιου ως φαρμακο |